Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-201 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TERN-201 | DRUG | Investigational drug |
| Placebo | OTHER | Matching placebo |
TERN-201 is an investigational small molecule being developed for the treatment of nonalcoholic steatohepatitis (NASH), a form of fatty liver disease. It is intended for patients with non-cirrhotic NASH, meaning the disease has not yet progressed to cirrhosis. The drug is currently in Phase 1 clinical development.
TERN-201 is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied for its effects on NASH, a metabolic liver disease. Its mechanism of action is not publicly detailed, and no target class has been specified in available information.
TERN-201 is being developed by Terns Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock is listed under the ticker symbol TERN on the NASDAQ exchange. Terns Pharmaceuticals focuses on developing treatments for metabolic diseases, including NASH.
TERN-201 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities such as the FDA. The drug is still being studied in early-stage clinical trials to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
TERN-201 has been studied in one clinical trial, the AVIATION Study (NCT04897594). This Phase 1 trial enrolled 52 patients with non-cirrhotic NASH and was completed. The study was uncontrolled, meaning there was no placebo or active comparator group, and it assessed safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
TERN-201 is a unique investigational compound and is not known to be the same as any other marketed drug. It is a small molecule developed by Terns Pharmaceuticals for NASH. No alternative names or aliases have been associated with TERN-201 in available information.